Australia – Yitu understands the bidding information of the fourth round of centralized drug procurement, the highest price reduction exceeds 96% | Australia Chinatown

Release your eyes, put on headphones, and listen~!
Introduction: This round of centralized procurement involves 45 varieties, including 8 major injection varieties such as pantoprazole for injection; this collection

Introduction: This round of centralized procurement involves 45 varieties, including 8 major injection varieties such as pantoprazole for injection. This centralized procurement of a total of 158 selected products, the average price reduction of the proposed selection is 52%, and the highest reduction is 96% .

The fourth round of national drug centralized procurement with volume was opened in Shanghai today.This round of centralized procurement involves 45 varieties and the highest procurement scale exceeds 250 billion yuan.

Among them, inhalation preparations were included in the national centralized procurement for the first time.At the same time, since the formal launch of the consistency evaluation of injections in May 2020, 5 injections such as pantoprazole for injection have also been included in this collection.

According to Xinhua News Agency, there were a total of 158 selected products in this centralized procurement. The average price of the selected products dropped by 52%, and the highest drop was 96%.According to preliminary estimates, the fourth batch of centralized procurement of medicines is expected to save 1 billion yuan in medicine costs a year.

01

Large varieties of injections are included in centralized procurement

本次纳入集采的45个品种中有8个注射剂品种、3个滴眼剂,其他均为口服剂型。45个产品包括7个国家医保甲类药品、35个乙类药品、2个非医保药品(分别为布洛芬注射液、注射用比伐芦定)。

8个注射剂品种分别为氨溴索注射剂、丙泊酚中长链脂肪乳、布洛芬注射液、多索茶碱注射剂、帕瑞昔布注射剂、泮托拉唑注射剂、硼替佐米注射剂和注射用比伐芦定。这些均为临床大品种,8个产品2019年样本医院收入占45个品种2019年总样本医院收入的30%以上。

According to data from Meinenet, the market size of terminal chemical injections for public medical institutions in China exceeded 2019 billion yuan in 6300, and the combined sales of the top 20 products exceeded 1000 billion yuan.

在厂商方面,此次集采涉及品种较多的进口企业分别有诺华(5个)、勃林格殷格翰(5个)、辉瑞(4个)和阿斯利康(3个);国产企业分别有石药集团(6个)、中国生物制药(5个)、翰森制药(4个)、恒瑞医药(3个)和科伦药业(3个)。

02

The average drop is at least 50%, and some varieties exceed 75%

The first three batches of nationally organized centralized drug procurement involved 112 varieties, and the average drop of selected products reached 54%.As of 2020, the actual purchase volume has reached 2.4 times the agreed purchase volume, and the overall cost savings have exceeded 1000 billion yuan.

With reference to previous experience, Nomura Orient International Securities predicts that the average drop in this centralized procurement will also exceed 50%.

According to the surging report, the information disclosed by the participating companies at the scene showed that the highest drop of varieties including sodium hyaluronate eye drops was as high as 75%.

03

Inhalation preparations are included in the national collection

It is worth noting that for the first time inhalation preparations are included in the national collection.

目前呼吸系统疾病在我国疾病死亡率中位居前五。2019年《柳叶刀》研究显示,我国20岁及以上人群哮喘患病率4.2%,患病人数总达4570万;20岁及以上人群COPD患病率8.6%,患病总人数将近1亿人次。患者基数庞大。

image

Image source: Guotai Junan Securities Research Report

In 2019, the global asthma/COPD drug market exceeded 200 billion U.S. dollars, and my country was about 200 billion yuan.Inhalation is the preferred method of administration.At present, the domestic production rate of inhalation preparations in my country is less than 10%.

Guotai Junan research believes that the incidence of asthma/COPD in China will continue to increase in the future due to factors such as the deterioration of the air environment, the increase in the smoking rate of the population, and the deepening of the aging of the population. At the same time, as the domestic diagnosis and treatment rate and control rate move closer to the United States, the patient base will continue to accumulate , New patients are superimposed on old patients, which brings huge demand for clinical medication.

Picture: The fourth batch of national procurement information

image

(Information source: Fengyun Yaotan compiled from public network information)

Reprint Statement: This article is reprinted and published, which only represents the attitude of the original author or the original platform, and does not represent our views.Only an information publishing platform is provided, and the article may be appropriately deleted.Contact the original author who has objections and requests for deletion.

"Chinatown" Fb shares selected Australian news daily, so that you can know the latest Australian news at anytime and anywhere @玩, @Immigration, @生活信息: https://www.fb.com/news.china.com.au/

[Welcome to the news to discuss cooperation! 】WeChat subscription account: news-china-com-au

Related posts

People have appreciated
Investment, financial management

Australia-Australia Finance Today|Australia restarts its tungsten mining project to break the Chinese monopoly; retail investors are scattered: GameStop drops more than 60% in a single day | Australia Chinatown

2021-2-6 21: 35: 23

Investment, financial management

Australia-"Not for sale!" American retail investors madly support GME, executives and PE giants make a fortune | Australia Chinatown

2021-2-6 21: 54: 08

0 replies AArticle author Madministrator
    No discussion yet, let me talk about your views
Personal center
shopping cart
coupon
Sign in today
New private message Private message list
Search
Fulfill your dreams!Sign up for $30